Partially thrombosed aneurysm after treatment with the flow diverter.

<p>CT angiograms showing a residual lumen within a large partially thrombosed fusiform aneurysm of the middle cerebral artery. Follow-up CTA (a) was performed 4 months and (b) 6 months after SFD (arrows) placement. The second follow-up study shows enlargement of the residual aneurysm lumen (arrow heads) and was performed after a new haemorrhage (not shown).</p

Effect of patient and procedure related variables on SFD deployment difficulty, flow disturbance, and delayed neurological complications.

<p>Untoward events reported during and after treatments related to aneurysm shapes, sizes location, and use of coils.</p><p>Deployment difficulty  =  poor opening, poor positioning, or migration of SFD.</p><p>Flow disturbance  =  partial or complete thrombosis of parent artery.</p

Timings and results of angiographic follow up.

<p>Plot of angiographic outcomes against follow up times in weeks.</p

Angiographic outcomes for the aneurysms treated with SFD.

<p>Angiographic outcomes for the cohort of aneurysms with complete follow up i.e. end of treatment and follow up angiogram.</p><p>Abbreviations: OG1 (complete occlusion); OG2 (neck remnant); OG3 (saccular filling).</p

Clinical complications observed in patients treated with SFD.

<p>Abbreviations: BA (basilar artery), PcomA (posterior communicating artery), CCA (carotid cavernous artery), MCA (middle cerebral artery), AICA (anterior inferior cerebellar artery), COA (carotid ophthalmic artery), S (saccular), F (fusiform), EVT (endovascular therapy).</p

Kinetics of the number of antigen-specific memory B-cells detected in the peripheral blood of infants after immunisation with different schedules of MenC conjugate vaccines, at each time-point following primary and booster vaccines, based on geometric mean concentrations for each study group at each visit.

<p>Kinetics of the number of antigen-specific memory B-cells detected in the peripheral blood of infants after immunisation with different schedules of MenC conjugate vaccines, at each time-point following primary and booster vaccines, based on geometric mean concentrations for each study group at each visit.</p

Proportion of MenC-specific memory B-cells out of the total pool of IgG positive memory B-cells detected in the peripheral blood at each time-point.

<p>IQR: Interquartile range.</p

Number of MenC-specific memory B-cells detected in the peripheral blood of infants 6 days after a Hib-MenC-TT booster at 12 months of age, according to different primary immunisation schedules (magnified from <b>Figure 3</b>).

<p>Number of MenC-specific memory B-cells detected in the peripheral blood of infants 6 days after a Hib-MenC-TT booster at 12 months of age, according to different primary immunisation schedules (magnified from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0101672#pone-0101672-g003" target="_blank"><b>Figure 3</b></a>).</p

Schedule of study visits and procedures, including vaccines administered and timing of blood draws used to measure MenC-specific memory B-cells.

<p>Schedule of study visits and procedures, including vaccines administered and timing of blood draws used to measure MenC-specific memory B-cells.</p

Number of children enrolled and included in the final analysis for MenC-specific memory B-cells.

<p>Number of children enrolled and included in the final analysis for MenC-specific memory B-cells.</p